{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:54:07Z","timestamp":1791849247053,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":115,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Paris Brain Initiative"},{"name":"Bertarelli Rare Cancer Initiative"},{"DOI":"10.13039\/100016394","name":"Ludwig Center at Harvard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016394","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DOD CDMRP"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01514-x","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:07:29Z","timestamp":1781914049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical responses to trastuzumab deruxtecan in molecularly defined ependymoma"],"prefix":"10.1038","volume":"10","author":[{"given":"L. Nicolas","family":"Gonzalez Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Joao","family":"Santiago-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Laurenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Coy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith L.","family":"Ligon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Touat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Santagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"1514_CR1","unstructured":"Central Nervous System Tumours: WHO Classification of Tumours. 5th ed. Lyon: International Agency for Research on Cancer. (2021)."},{"key":"1514_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bpa.12866","volume":"30","author":"DW Ellison","year":"2020","unstructured":"Ellison, D. W. et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol. 30, 863\u2013866 (2020).","journal-title":"Brain Pathol."},{"key":"1514_CR3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","volume":"27","author":"KW Pajtler","year":"2015","unstructured":"Pajtler, K. W. et al. Molecular classification of ependymal tumors across all CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell 27, 728\u2013743 (2015).","journal-title":"Cancer Cell"},{"key":"1514_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-031-53578-9_2","volume":"50","author":"ST J\u00fcnger","year":"2024","unstructured":"J\u00fcnger, S. T., Zschernack, V., Messing-J\u00fcnger, M., Timmermann, B. & Pietsch, T. Ependymoma from benign to highly aggressive diseases: a review. Adv. Tech. Stand Neurosurg. 50, 31\u201362 (2024).","journal-title":"Adv. Tech. Stand Neurosurg."},{"key":"1514_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/neuonc\/noad205","volume":"26","author":"S Coy","year":"2024","unstructured":"Coy, S. et al. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Neuro Oncol. 26, 458\u2013472 (2024).","journal-title":"Neuro Oncol."},{"key":"1514_CR6","doi-asserted-by":"publisher","unstructured":"Gonzalez Castro L. N., Santagata S. Antibody-drug conjugates for primary brain tumors. Front. Oncol. [cited 2026 Apr 22];16. Available from: https:\/\/doi.org\/10.3389\/fonc.2026.1811494\/full (2026).","DOI":"10.3389\/fonc.2026.1811494\/full"},{"key":"1514_CR7","doi-asserted-by":"publisher","first-page":"103699","DOI":"10.1016\/j.esmoop.2024.103699","volume":"9","author":"M Vaz Batista","year":"2024","unstructured":"Vaz Batista, M. et al. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial. ESMO Open 9, 103699 (2024).","journal-title":"ESMO Open"},{"key":"1514_CR8","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck, N. et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat. Med. 30, 3717\u20133727 (2024).","journal-title":"Nat. Med."},{"key":"1514_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/1078-0432.CCR-22-1138","volume":"29","author":"S Kabraji","year":"2023","unstructured":"Kabraji, S. et al. Preclinical and clinical efficacy of Trastuzumab Deruxtecan in breast cancer brain metastases. Clin. Cancer Res. 29, 174\u2013182 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1514_CR10","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi, S. et al. Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med 382, 610\u2013621 (2020).","journal-title":"N. Engl. J. Med"},{"key":"1514_CR11","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA Topoisomerase I Inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res 22, 5097\u20135108 (2016).","journal-title":"Clin. Cancer Res"},{"key":"1514_CR12","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.annonc.2024.08.2347","volume":"35","author":"F Andr\u00e9","year":"2024","unstructured":"Andr\u00e9, F. et al. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. Ann. Oncol. 35, 1169\u20131180 (2024).","journal-title":"Ann. Oncol."},{"key":"1514_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00401-019-02056-2","volume":"138","author":"DR Ghasemi","year":"2019","unstructured":"Ghasemi, D. R. et al. MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol. 138, 1075\u20131089 (2019).","journal-title":"Acta Neuropathol."},{"key":"1514_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40478-020-00973-y","volume":"8","author":"M Raffeld","year":"2020","unstructured":"Raffeld, M. et al. High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. Acta Neuropathol. Commun. 8, 101 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"1514_CR15","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor Receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J. Clin. Oncol. 36, 2105\u20132122 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1514_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med"},{"key":"1514_CR17","doi-asserted-by":"publisher","first-page":"e31657","DOI":"10.7554\/eLife.31657","volume":"7","author":"J-R Lin","year":"2018","unstructured":"Lin, J.-R. et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife 7, e31657 (2018).","journal-title":"Elife"},{"key":"1514_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature13108","volume":"506","author":"SC Mack","year":"2014","unstructured":"Mack, S. C. et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506, 445\u2013450 (2014).","journal-title":"Nature"},{"key":"1514_CR19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/path.4682","volume":"238","author":"MS Abedalthagafi","year":"2016","unstructured":"Abedalthagafi, M. S. et al. Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. J. Pathol. 238, 584\u2013597 (2016).","journal-title":"J. Pathol."},{"key":"1514_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00605-3","volume":"10","author":"JL Guerriero","year":"2024","unstructured":"Guerriero, J. L. et al. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ Breast Cancer 10, 2 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"1514_CR21","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","volume":"25","author":"NL Albert","year":"2024","unstructured":"Albert, N. L. et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 25, e29\u2013e41 (2024).","journal-title":"Lancet Oncol."},{"key":"1514_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/neuonc\/nox179","volume":"20","author":"TP Heffron","year":"2018","unstructured":"Heffron, T. P. Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels. Neuro Oncol. 20, 307\u2013312 (2018).","journal-title":"Neuro Oncol."},{"key":"1514_CR23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/neuonc\/noaa240","volume":"23","author":"MR Gilbert","year":"2021","unstructured":"Gilbert, M. R. et al. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro Oncol. 23, 468\u2013477 (2021).","journal-title":"Neuro Oncol."},{"key":"1514_CR24","first-page":"3054","volume":"8","author":"RJ Gilbertson","year":"2002","unstructured":"Gilbertson, R. J. et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin. Cancer Res 8, 3054\u20133064 (2002).","journal-title":"Clin. Cancer Res"},{"key":"1514_CR25","doi-asserted-by":"crossref","unstructured":"Griesinger A. M., et al. Molecular biology and Phase 1 Study of GM-CSF and Intrathecal Trastuzumab in children with recurrent posterior Fossa Ependymoma. Neuro Oncol 2026;noag066.","DOI":"10.1093\/neuonc\/noag066"},{"key":"1514_CR26","doi-asserted-by":"publisher","first-page":"e29316","DOI":"10.1002\/pbc.29316","volume":"69","author":"P Varlet","year":"2022","unstructured":"Varlet, P. et al. Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma. Pediatr. Blood Cancer 69, e29316 (2022).","journal-title":"Pediatr. Blood Cancer"},{"key":"1514_CR27","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1200\/JCO.2010.28.4687","volume":"28","author":"M Fouladi","year":"2010","unstructured":"Fouladi, M. et al. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J. Clin. Oncol. 28, 4221\u20134227 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1514_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11060-015-1764-7","volume":"123","author":"M DeWire","year":"2015","unstructured":"DeWire, M. et al. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). J. Neurooncol. 123, 85\u201391 (2015).","journal-title":"J. Neurooncol."},{"key":"1514_CR29","doi-asserted-by":"publisher","first-page":"1748353","DOI":"10.3389\/fonc.2026.1748353","volume":"16","author":"M Maccari","year":"2026","unstructured":"Maccari, M. et al. Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review. Front Oncol. 16, 1748353 (2026).","journal-title":"Front Oncol."},{"key":"1514_CR30","doi-asserted-by":"publisher","first-page":"iii37","DOI":"10.1093\/neuonc\/now070.32","volume":"18","author":"DS Osorio","year":"2016","unstructured":"Osorio, D. S. et al. EPN-33 feasibility and tolerability of intravenous and intraventricular Trastuzumab in HER2-positive recurrent metastatic ependymoma. Neuro Oncol. 18, iii37\u201338 (2016).","journal-title":"Neuro Oncol."},{"key":"1514_CR31","doi-asserted-by":"publisher","first-page":"i80","DOI":"10.1093\/neuonc\/noy059.233","volume":"20","author":"A Nellan","year":"2018","unstructured":"Nellan, A. et al. EPEN-33. Study of anti-HER2 CAR T cells in the immunosuppressive ependymoma tumor microenvironment. Neuro Oncol. 20, i80 (2018).","journal-title":"Neuro Oncol."},{"key":"1514_CR32","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1158\/1078-0432.CCR-24-3083","volume":"31","author":"S Mehta","year":"2025","unstructured":"Mehta, S. et al. B7-H3 CAR T cells are effective against ependymomas but limited by tumor size and immune response. Clin. Cancer Res. 31, 3754\u20133770 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1514_CR33","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & de Vries, E. G. E. The journey of antibody\u2013drug conjugates: lessons learned from 40 years of development. Cancer Discov. 14, 2089\u20132108 (2024).","journal-title":"Cancer Discov."},{"key":"1514_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang, R. et al. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J. Hematol. Oncol. 18, 51 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"1514_CR35","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","volume":"20","author":"MJ Mair","year":"2023","unstructured":"Mair, M. J. et al. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. Nat. Rev. Clin. Oncol. 20, 372\u2013389 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1514_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.2868","volume":"46","author":"PK Brastianos","year":"2014","unstructured":"Brastianos, P. K. et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat. Genet. 46, 161\u2013165 (2014).","journal-title":"Nat. Genet."},{"key":"1514_CR37","doi-asserted-by":"publisher","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","volume":"108","author":"PK Brastianos","year":"2016","unstructured":"Brastianos, P. K. et al. Dramatic response of BRAF V600E mutant papillary Craniopharyngioma to Targeted Therapy. J. Natl. Cancer Inst. 108, djv310 (2016).","journal-title":"J. Natl. Cancer Inst."},{"key":"1514_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2213329","volume":"389","author":"PK Brastianos","year":"2023","unstructured":"Brastianos, P. K. et al. BRAF-MEK inhibition in newly diagnosed papillary Craniopharyngiomas. N. Engl. J. Med 389, 118\u2013126 (2023).","journal-title":"N. Engl. J. Med"},{"key":"1514_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32430-w","volume":"13","author":"S Coy","year":"2022","unstructured":"Coy, S. et al. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Nat. Commun. 13, 4814 (2022).","journal-title":"Nat. Commun."},{"key":"1514_CR40","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1038\/s41596-019-0206-y","volume":"14","author":"Z Du","year":"2019","unstructured":"Du, Z. et al. Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nat. Protoc. 14, 2900\u20132930 (2019).","journal-title":"Nat. Protoc."},{"key":"1514_CR41","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1093\/bioinformatics\/btac544","volume":"38","author":"JL Muhlich","year":"2022","unstructured":"Muhlich, J. L. et al. Stitching and registering highly multiplexed whole-slide images of tissues and tumors using ASHLAR. Bioinformatics 38, 4613\u20134621 (2022).","journal-title":"Bioinformatics"},{"key":"1514_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41592-021-01308-y","volume":"19","author":"D Schapiro","year":"2022","unstructured":"Schapiro, D. et al. MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging. Nat. Methods 19, 311\u2013315 (2022).","journal-title":"Nat. Methods"},{"key":"1514_CR43","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.21105\/joss.02579","volume":"5","author":"J Hoffer","year":"2020","unstructured":"Hoffer, J. et al. Minerva: a light-weight, narrative image browser for multiplexed tissue images. J. Open Source Softw. 5, 2579 (2020).","journal-title":"J. Open Source Softw."},{"key":"1514_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41551-021-00789-8","volume":"6","author":"R Rashid","year":"2022","unstructured":"Rashid, R. et al. Narrative online guides for the interpretation of digital-pathology images and tissue-atlas data. Nat. Biomed. Eng. 6, 515\u2013526 (2022).","journal-title":"Nat. Biomed. Eng."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01514-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01514-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01514-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:22:40Z","timestamp":1791847360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01514-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1514"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01514-x","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S. Santagata reports personal fees from Roche and grants from Merck outside the submitted work. L.N. Gonzalez Castro reports consulting fees from Elsevier, BMJ Best Practice, Prime, Medscape, and Servier, and research funding from Merck & Co, and Amgen outside the submitted work. N. Lin reports institutional research support from Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, AstraZeneca, and Consulting Honoraria from Seattle Genetics, Daiichi Sankyo, AstraZeneca, Olema Pharmaceuticals, Stemline\/Menarini, Artera Inc., Eisai, and Shorla Oncology. K. Ligon reports being a founder and equity holder in Travera Inc. (consulting) and reports receiving consulting fees from Bristol Myers Squibb (BMS), Integragen, Servier, LEK, and Blaze Biosciences, as well as research funding to his institution (DFCI) from BMS and Lilly. No disclosures were reported by the other authors.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"383"}}